Furthermore, multiple anti-CEACAM6 agents that exhibit favorable therapeutic effects in preclinical pancreatic adenocarcinoma models have been developed [17,25,26,27]. The gene discussed is CEACAM6; the disease is pancreatic adenocarcinoma.